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Abstract  
Objective: To address concerns over the psychological impact of being on a monitoring 
pathway following prostate cancer (PCa) diagnosis, this study compared the psychological 
status of men on active surveillance (AS) or watchful waiting (WW) with men on active 
treatment (AT), and explored psychological adjustment in men on AS/WW.  
Methods: Cross-sectional survey of UK men diagnosed with PCa 18-42 months previously 
(n=16,726, localised disease at diagnosis) and telephone interviews with 24 men on AS/WW. 
Psychological outcomes were measured using two validated scales (Short Warwick-
Edinburgh Mental-Well-being Scale; Kessler Psychological Distress Scale). Univariable and 
multivariable analyses compared outcomes between men on AS/WW and AT. Thematic 
analysis of interviews was undertaken, informed by a previously developed theory of 
adjustment to cancer. 
Results: 3,986 (23.8%) respondents were on AS/WW. Overall, psychological outcomes were 
similar or better in men on AS/WW compared to those receiving AT (SWEMWBS: Poor well-
being; 12.3% AS/WW vs 13.9% AT, adjusted OR=0.86, 95% CI 0.76-0.97; K6: severe 
psychological distress; 4.6% vs 5.4%, adjusted OR=0.90, 95% CI 0.74-1.08). Interviews 
indicated most men on AS/WW had adjusted positively. Men with poorer well-being were 
less able to accept, reframe positively and normalise the diagnosis, described receiving 
insufficient information and support, and a lack of confidence in their health-care 
professionals.   
Conclusions: Most men on AS/WW cope well psychologically. Men making treatment 
decisions should be given this information. Psychological health should be assessed to 
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determine suitability for AS/WW, and at monitoring appointments. A clear action plan and 
support from healthcare professionals is important.   
Introduction 
Prostate cancer (PCa) is the most common cancer in men in Europe [1]. Many men have 
localised disease with treatment options being one or a combination of prostatectomy, 
radiotherapy or active surveillance (AS).  Following concerns regarding over-treatment, AS is 
now offered to all men diagnosed with localised, low-risk PCa [2], as a way to avoid 
treatment-related impairments in urinary, bowel and sexual functioning [3-5]. AS is also an 
option for men with intermediate risk disease [6]. Men on AS typically undergo periodic 
Prostate-Specific Antigen (PSA) testing, Digital Rectal Examinations (DRE), MRI scans and 
biopsies with a view to moving to radical intervention if the disease progresses [7]. Watchful 
Waiting (WW) is another alternative to active treatment (AT), although this is typically 
offered to older men and/or men with pre-existing health conditions or more advanced PCa 
[8].  
Concerns have been raised over the psychological impact of being on an AS/WW regime.  
Systematic reviews of quantitative studies suggest quality of life and psychological well-
being in men on AS/WW is generally good and comparable to [9-13], or better than, [10, 14] 
men who received AT. However, evidence from qualitative studies suggests men on AS/WW 
may struggle with anxiety [15-20]. Further exploration is needed to understand how men 
adjust to being on AS/WW. 
The Life After Prostate Cancer Diagnosis (LAPCD) study is a UK-wide mixed methods study 
[21], which ĂŝŵĞĚƚŽĞǆƉůŽƌĞƚŚĞŝŵƉĂĐƚŽĨWĂŽŶŵĞŶ ?ƐǁĞůů-being through a large-scale 
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survey of men with PCa and interviews with a sub-sample. In this paper we a) compared the 
psychological outcomes in men with localised disease on AS/WW and men who received AT, 
using survey responses, and b) explored the psychological adjustment of all interviewees on 
AS/WW, drawn from the total sample of interviewed men, to inform how future health 
services may best support this growing group of men. 
Methods 
Design 
Full methodological details can be found in the protocol [21]. Ethical and regulatory 
approvals were obtained (Newcastle and North Tyneside Research Ethics Committee 
(15/NE/0036), Health Research Authority Confidentiality Advisory Group (15/CAG/0110), 
NHS Scotland Public Benefit and Privacy Panel (0516-0364)). In brief, all men who were 18-
42 months post diagnosis of PCa were identified through cancer registries in England, Wales 
and Northern Ireland and through hospital activity data in Scotland, and invited by their 
treating centre to complete a postal questionnaire. Respondents indicated on the 
questionnaire willingness to be interviewed. COREQ reporting guidelines were followed [22]. 
Data collection 
Measures 
The questionnaire included socio-demographic items including: age, ethnicity, long term 
conditions (LTCs), marital status, sexuality, employment status, caring responsibilities, and 
previous professional help-seeking for mental health or alcohol-related problems. 
Treatment was self-reported. An area-based measure of socioeconomic deprivation (Index 
of Multiple Deprivation) was obtained using postcode at diagnosis.  
5 
 
Validated outcome measures included the Short Warwick-Edinburgh Mental-Well-being 
Scale (SWEMWBS) [23] and the six item version of the Kessler Psychological Distress Scale 
(K6) [24] (see supplementary file 1). The SWEMWBS aims to measure psychological well-
being through items relating to ƉĂƌƚŝĐŝƉĂŶƚƐ ?ƚŚŽƵŐŚƚƐĂŶĚĨĞĞůŝŶŐƐ ‘ŽǀĞƌƚŚĞƉĂƐƚƚǁŽ
ǁĞĞŬƐ ? ?^ĐŽƌĞƐƌĂŶŐĞĨƌŽŵ ?-35 and it is suggested scores A?19.25 indicate poor well-being 
[25]. The K6 measure assesses nonspecific psychological distress. Scores range from 6-30, 
with a cut-off of A?19 indicating severe psychological distress [26].  
Interviews 
Interview participants were recruited following survey completion. For the main LAPCD 
study of all interviewed men, a purposive sampling frame was developed, stratified by 
treatment type. We included unpartnered, Black Asian and Minority Ethnic (BAME) and 
gay/bisexual men and men from different geographical locations. We also included a range 
of men with regards to level of physical and psychological functioning as shown in their 
survey responses. 
A semi-structured interview topic guide (see supplementary file 2) was developed in 
collaboration with the study clinical and patient advisory groups, and informed by previous 
research [19]. This included questions regarding the physical, emotional, sexual and 
psychosocial impact of PCa and experiences of health services. Interviewers were guided by   
ƉĂƌƚŝĐŝƉĂŶƚƐ ? responses. Telephone interviews lasted 50 minutes on average. Interviews 
were transcribed verbatim. 
Data Analysis  
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Analyses were restricted to individuals with a diagnosis of localised PCa (stage I/II), 
according to cancer registration data.  Descriptive statistics compared men  on AS/WW and 
those who received AT in terms of sociodemographic variables, other patient factors, and 
psychological outcomes (well-being and psychological distress). As there is non-standard 
usage of the terms AS and WW and they are sometime used interchangeably, similar to 
previous work [27, 11], men on AS and WW were combined .  
Chi-square tests compared categorical variables and T-tests were used for continuous 
variables. Multivariable logistic regression analyses compared psychological outcomes in the 
AS/WW and AT groups, after adjustment for relevant sociodemographic and other patient 
factors. Analyses were repeated with poor psychological well-being (SWEMWBS score 
A?19.25) and severe psychological distress (K6 score A?19) as the outcome. Missing data were 
excluded on a question-by-question basis, thus all results refer to the men who responded 
to that question. Stata v15.0 was used for all analyses. A p value of <.05 was used to indicate 
significance.  
Interviews 
A thematic analysis was undertaken of all interviewed men for the main LAPCD study using a 
Framework approach, involving seven stages [28, 29]. Familiarisation was followed by 
independent inductive coding and group discussion of the first five transcripts 
(LM,EW,CR,JN,RW). A coding framework was developed (see supplementary file 3), which 
was primarily informed by these discussions but also using themes deduced from the topic 
guide. The framework was then iteratively refined following further interviews and initial 
coding, and was discussed with the LAPCD user advisory group. All interview transcripts 
were uploaded onto NVivo [30] and indexed, which involved identification of sections of 
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data corresponding to each coding frame. Researchers summarised each section of 
transcript into coding summaries in the coding framework.  
Subgroup analysis  
We extracted all men on AS/WW from the whole interview dataset for separate analysis. 
This involved collation of all coding frames of all men on AS/WW, with a focus on those 
relevant to the psychological and social impact of PCa. Descriptive themes were then 
developed and it became apparent the themes corresponded to those in a theory of 
adjustment to testicular cancer [31]. The data were therefore able to test the theory with 
reference to the process of positive adjustment in men on AS/WW. Most authors were not 
involved in the original theory development [31], and so were able to maintain a critical 
distance from the data. Most of the main themes in this theory, presented as processes, 
were used (see Figure 1), with some requiring minor modification, such as process 3 which 
has been altered to reflect that men on AS/WW did not receive treatment.  
Findings 
Survey data 
Descriptive statistics 
In the LAPCD sample, 35,823 men returned a completed questionnaire (60.8% response; 
19,599 with stage I/II disease (61.3% response). Of those with stage I/II disease, 16,726 men 
provided valid treatment data. A quarter of these (3,986; 23.8%) reported they were on AS 
(N = 2,320) or WW (N = 1,666). No significant differences were found between men on 
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AS/WW and men undergoing AT with respect to sociodemographic and patient factors, 
apart from socioeconomic deprivation (Table 1). 
A SWEMWBS score was available for 3,747 (94.0%) of the AS/WW group and 12,000 (94.2%) 
of the AT group (surgery, radiotherapy, ADT).  A lower proportion of men in the AS/WW 
group reported poor emotional well-being according to the cut-off (12.3%, N=462) 
compared to the AT group (13.9%, N=1665; p=0.02) (see Table 2). A K6 score was available 
for 3,799 (95.3%) of the AS/WW group and 12,190 (95.7%) of the AT group. There was a 
smaller, non-significant, difference in the proportion of men reporting severe psychological 
distress based on the cut-off (AS/WW: 4.6%, N = 174 vs AT: 5.4%, N = 656; p =0.05).  
When comparing the characteristics of men on AS or WW, men on AS were significantly 
younger than men on WW (Mean = 68.4 years vs. 73.8 years, p <0.001) and reported fewer 
LTCs (p<0.001). However, no differences in well-being or distress were found between the 
AS and WW groups.  
Multivariable analyses 
After adjustment for sociodemographic and other patient factors, the odds of reporting 
poor well-being were lower in men on AS/WW than those receiving AT (OR=0.86, 95% CI 
0.76-0.97)(Table 2). There was no difference in the odds of reporting severe psychological 
distress between the men on AS/WW and AT (OR=0.90, 95% CI 0.74-1.08).  
Interview data 
Participant characteristics of the interview sub-set of men on AS/WW are reported (see 
supplementary file 4). The majority of men on AS/WW had made a positive adjustment to 
their diagnosis and AS/WW pathway with a minority struggling to do so. Positive adjustment 
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centred around a process of dismantling the threats of cancer and the impact of being on a 
monitoring pathway. This involved six key processes (Figure 1[31]).  
Herein, we describe the processes through which men were able to adjust positively to PCa 
and being on a monitoring pathway and, for some, the barriers to doing so (i.e. negative 
adjustment).  
Process 1: Appraisal of PCa as a minimal threat (vs. significant threat)   
While the diagnosis of PCa was sometimes described as an emotionally difficult period 
ŝŶǀŽůǀŝŶŐ ‘shock ?ĂŶĚ ?ǁŽƌƌǇ ?, most men appeared to have adjusted positively to both their 
diagnosis and being on AS/WW. Many appraised the current impact of PCa as minimal in 
terms of their overall health and well-being with some feeling it had never really had any 
impact ( ?ŝƚ ?ƐŶŽƚĂďŝŐĚĞĂů ?). Men also held positive appraisals of being on a monitoring 
pathway.  
 “/ƚ ?ƐŵĂĚĞŶŽĚŝĨĨĞƌĞŶĐĞƚŽŵǇůŝĨĞǁŚĂƚƐŽĞǀĞƌ apart from having to go and have 
pretty regular check-ups ? ?P24, WW, 70 years)  
Only four men expressed a greater or more enduring impact on their lives, attributing this to 
the greater psychological threat of cancer rather than any physical impact.  
 “It ŚĂƐŶ ?ƚŚĂĚĂŶǇƐŝŐŶŝĨŝĐĂŶƚĐůŝŶŝĐĂůŝŵƉĂĐƚǇĞƚ ?ƵƚƉƐǇĐŚŽůŽŐŝĐĂůůǇŽĨĐŽƵƌƐĞŝƚǁĂƐ
devastating for me ?(P3, AS, 58 years)  
 
 
Process 2: Positive Reframing of the threats of PCa (vs. holding a generalised view of 
cancer) 
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Perceiving PCa specifically as a cancer with a good prognosis facilitated positive adjustment. 
Participants often reframed PCa positively as ĂĐĂŶĐĞƌƚŚĞǇǁŽƵůĚ ‘ĚŝĞǁŝƚŚĂŶĚŶŽƚŽĨ ? and 
generally held positive expectations towards the future  ? ?ƚŚĞĨƵƚƵƌĞƚŽŵĞŝƐĨŝŶĞ ?).   
 “/ĨǇŽƵ ?ƌĞŐŽŝng to have cancer, prostate cancer is probably one of the better ones to 
have ? (P9, AS, 64 years) 
Conversely, perceiving the disease negatively in more generalised terms meant a few 
participants struggled to get away from the negative connotations of cancer, and its 
association with death. These perceptions could be exacerbated by the media, knowing 
friends or family members who had died of cancer, or men reporting having personality 
traits such as neuroticism, which translated into greater fears over their PCa.  
 “/ƚ ?ƐƚŚĞƌĞŝŶƚŚĞďĂĐŬŽĨǇŽƵƌŵŝŶĚ ?ĐĂŶĐĞƌ ?ƐĂŶĂǁĨƵůǁŽƌĚ ?ŶŽŵĂƚƚĞƌǁŚŝĐŚǁĂǇ
you look at it ? ?P6, AS, 70 years) 
Positive reframing was also facilitated by making comparisons to others perceived as worse 
off, including other PCa patients on AT or those with different cancers or other illnesses, 
enabling them to put their own diagnosis into perspective. Comparisons to other life events 
that had been worse also helped them reframe their diagnosis in a positive light.  
 “ ? ?ƐŽŵĞƚŝŵĞƐǇŽƵũƵƐƚĨĞĞů ?life is tough ? ?Ƶƚ ?ŝƚ ?ƐŶŽƚƚŚĞǁŽƌƐƚĐĂƐĞƐĐĞŶĂƌŝŽĂŶĚ
people have far worse conditions and far worse diagnoses than I have, so therefore 
ŝƚ ?ƐŶŽƚƐŽŵĞƚŚŝŶŐƚŽǁŽƌƌǇƚŽŽŵƵĐŚĂďŽƵƚ ?(P7, AS, 53 years) 
Process 3: Taking an independent approach and getting on with life (vs. struggling to get 
on with life)  
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Most participants preferred to take an independent approach and described getting on with 
life, not feeling the need to utilise support services, whether NHS, charities or PCa support 
groups. Some felt further support would only be needed should they require treatment. The 
diagnosis was not commonly disclosed outside their immediate families, as men often felt 
there was no need to gain support and/or did not perceive the diagnosis as particularly 
threatening.   
"/ ?ǀĞŶĞǀĞƌƌĞĂůůǇƐĂŝĚƚŽĂŶǇďŽĚǇ,  ?/ ?ǀĞŐŽƚƉƌŽƐƚĂƚĞĐĂŶĐĞƌ ? ?EŽƚďĞĐĂƵƐĞŝƚ ?ƐƚŚĞ
ǁŽƌĚĐĂŶĐĞƌďƵƚ ?ǁŝƚŚƚŚĞĨĞǁĐĞůůƐǁŝƚŚŽŶĞƐĂŵƉůĞŝƚ ?ƐǀĞƌǇƐĞƌŝŽƵƐǇĞƚ ? ? (P21, WW, 
69 years) 
In contrast, some men who were struggling more discussed the importance of additional 
psychological support being available for men on AS/WW. 
 “dhe area that needs to be improved is the psychological support. Not everybody will 
ǁĂŶƚŝƚŽƌŶĞĞĚŝƚ ?ďƵƚ/ĚŽƚŚŝŶŬŝƚŶĞĞĚƐƚŽďĞŵŽƌĞƉƌŽĂĐƚŝǀĞ ? ?(P3, AS, 58 years) 
Process 4: Acceptance and normalisation of cancer diagnosis (vs. struggling to accept and 
normalise PCa diagnosis)  
Acceptance and normalisation of the diagnosis of PCa as relatively common in older men 
helped men dismantle the threat of cancer, facilitating positive adjustment. Some reflected 
that at their age they would eventually die of something. 
  “At 75, ŝƚ ?ƐũƵƐƚŽŶĞŽĨƚŚŽƐĞƚŚŝŶŐƐ ? /ƚ ?ƐůŝĨĞ ?(P5, AS, 75 years).  
Others reported they were pleased to know their diagnosis and to be monitored while other 
men their age might have PCa and not be aware of it.  Whilst some men initially struggled to 
accept and normalise their diagnosis this was felt to improve with the passing of time in 
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some.  
  “/ ?ǀĞŐƌŽǁŶƚŽĂĐĐĞƉƚŝƚ ?ƐƚŝŵĞ ?ƐŐŽŶĞŽŶ ?ǇŽƵjust sort of accept it more..  put it to 
ƚŚĞďĂĐŬŽĨǇŽƵƌŵŝŶĚĂƐŵƵĐŚĂƐǇŽƵĐĂŶ ? ?(P14, AS, 56 years) 
Process 5: Preserving the normal self (vs. holding greater illness centrality)  
For most men, the impact on their self-identities appeared to be minimal, and some did not 
identify as a cancer patient. Most men also reported little impact on their social or working 
lives, and felt normality had been restored.  
 “/ŶĞǀĞƌƚŚŝŶŬ P ?ŽŚŵǇŐŽŽĚŶĞƐƐ ?/ ?ǀĞŐŽƚƉƌŽƐƚĂƚĞĐĂŶĐĞƌ ? other than talking with you 
 ?Žƌ ?ǁŚĞŶ/ĨŝůůŝŶŵĞĚŝĐĂůƋƵĞƐƚŝŽŶŶĂŝƌĞƐ ? (P20, WW, 66 years)  
Conversely, for men whose struggles were predominantly psychological, PCa appeared to be 
more central and impactful on their lives and self-identities.  
 “/ ?ǀĞŚĂĚƚŽĨĂĐĞƵƉƚŽƚŚĞŝƐƐƵĞƐŽĨŵŽƌƚĂůŝƚǇĂŶĚƉŽƚĞŶƚŝĂůĨŽƌƚŚŝƐƚŽĂĐƚƵĂůůǇĐŚĂŶŐĞ
my life very quickly.. ^ŽŝŶƚŚĂƚǁĂǇŝƚ ?ƐŵĂĚĞŵĞ ?/ƐĞůĨ-ŝĚĞŶƚŝĨǇŝŶĂĚŝĨĨĞƌĞŶƚǁĂǇ ?
(P3, AS, 58 years) 
Process 6: Re-establishing a sense of security and letting go of fears (vs. struggling with 
uncertainty)  
Re-establishing a sense of security following diagnosis helped facilitate positive adjustment. 
This was influenced by a strong sense of trust and confidence in the health care team, 
including good communication, a plan of action and continuity of care. Gaining reassurance 
their disease was low grade and contained was also important, as was receipt of stable PSA 
tests. Some participants discussed the value of receiving signposts to information resources 
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which increased their confidence over future treatment and empowered men to ask health 
professionals more detailed questions about AS/WW.   
 “ŵŽƚŝŽŶĂůůǇ/ĚŽŶ ?ƚŚĂǀĞĂƉƌŽďůĞŵ ? ?ĞĐĂƵƐĞ/ĨĞĞůƚŚĂ ƚŚĞE,^ĂƌĞƉĂǇŝŶŐ
attention to me and are doing thĞŝƌũŽď ? ?They have stuck to what they have said and 
they have listened to me, talked to me and advised me" (P18, WW, 73 years) 
The few participants who were less well-adjusted appeared more dissatisfied with their past 
and/or current care, including support and information received. A lack of information or 
discussions on potential future treatments seemed to exacerbate uncertainties and made 
ŵĞŶĨĞĞů ‘ůĞĨƚŝŶƚŚĞĚĂƌŬ ? and worried about the future. A few expressed concerns over 
future treatment side effects. A lack of rapport with their health professional or feeling they 
had limited information  contributed to feelings of disempowerment.  
 “ůŝƚƚůĞďŝƚƵƉƐĞƚ ?ĚŝƐĂƉƉŽŝŶƚĞĚ ?ǁŽƌƌŝĞĚǁŚĂƚƚŚĞĨƵƚƵƌĞŚŽůĚƐ ?/ ?ŵǁŽƌƌŝĞĚŵŽƌĞ
ĂďŽƵƚǁŚĂƚƚŚĞƚƌĞĂƚŵĞŶƚŽƉƚŝŽŶƐǁŝůůďĞ ?(P1, AS, 53 years) 
Most participants referred to the uncertainty associated with not knowing if and when PCa 
may progress, and anxiety leading up to PSA testing was common. However, many reported 
increasing tolerance of this uncertainty and greater ability to get on with life and to let go of 
fears. 
 “ƐƚŝŵĞŐŽĞƐďǇĂŶĚŶŽƚŚŝŶŐŝƐŐĞƚƚŝŶŐǁŽƌƐĞ/ ?ŵŐĞŶĞƌĂůůǇŵŽƌĞƌĞĂƐƐƵƌĞĚĂŶĚ/ũƵƐƚ
ĐĂƌƌǇŽŶǁŝƚŚůŝĨĞĂƐƉĞƌŶŽƌŵĂů ? (P22, AS or WW*, 68 years) 
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A few men struggled more in dealing with uncertainty. Men were helped in tolerating 
uncertainty by the knowledge they were avoiding the side effects of AT and, should they 
need them, they might benefit from improved treatments in the future.   
Discussion 
This is the largest study of well-being in men on AS/WW to date. Survey findings suggest, 
overall, psychological well-being is good in men who have been on AS/WW for >18 months, 
and equivalent to or better than those on AT. These findings have been confirmed by 
interviews, which provide an insight into how most men adjusted positively to being on a 
monitoring pathway, whilst a minority adjusted less well. Positive adjustment has been 
conceptualised using a modified theory of adjustment to cancer [31]. 
Our findings are broadly consistent with previous quantitative studies [9-13], but appear to 
differ from some previous qualitative research, that reports persistent worry, altered social 
activities and greater psychological needs in men on AS/WW [15-18]. These studies were, 
however, based on much smaller samples of men on WW (<10 participants) [15, 16], those 
who switched from AS to AT [18] or focused on men closer to diagnosis. Men in our sample 
were 18-42 months post-diagnosis and it is possible those initially on AS experiencing 
greater anxiety had opted for AT within the study time-frame. While previous work [32] 
suggests a quarter of men on AS received AT within three years, the reasons behind this 
change are unclear.   
Our interview findings highlight several factors influencing adjustment. As previously shown 
for PCa [33] and other cancer types [31, 34-36], illness perceptions were important in  
adjustment, influencing positive reframing and were often shaped by health professionals 
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discussing the generally positive prognosis [31]. A nurse-led intervention to help men on 
WW cognitively reframe their diagnosis indicated uncertainty can be reduced and quality of 
life improved [37], but further larger scale work is warranted. Most men on AS did not feel 
they needed additional support services, so resources or future interventions should be 
targeted to patients with psychological problems, rather than all men on AS/WW. Similar to 
the theory used [31], acceptance and normalisation of their diagnosis, low illness centrality 
and positive reframing influenced positive adjustment, confirming previous findings in PCa 
patients [19, 20] and other cancer types [31, 34, 38].  
These findings extend the theory employed [31] to illustrate the importance of having trust 
and confidence in health professionals to promote ŵĞŶ ?Ɛ feelings of security from the threat 
of PCa monitoring. Previous studies have reported similar findings [15, 16, 39, 20]. A lack of 
confidence, information and reassurance were indicators of poorer adjustment, and some 
wanted greater information, particularly regarding future treatments. Elsewhere, predictors 
of poorer adjustment have included younger age, fear of recurrence, and 
misunderstandings towards active monitoring [11, 40, 20].   
Clinical Implications  
Clinicians should ensure men diagnosed with localised PCa fully understand the potentially 
indolent trajectory of PCa and that most men have positive psychological outcomes whilst 
on AS/WW. Patients on AS should have a clear plan of action regarding their surveillance 
protocol and should know when to expect investigations and subsequent results. Health 
professionals should routinely ask men about their psychological health at monitoring 
appointments, and use distress screening tools at diagnosis to assess suitability for AS/WW. 
Men who are struggling with managing distress should be offered an opportunity to discuss 
16 
 
their concerns and offered information and support. Future research needs to develop tools 
that might facilitate such discussions, and indicate ways men might be encouraged to seek 
psychological support. Health professionals have a key role in helping to shape positive 
perceptions towards AS/WW pathways, helping men positively reframe and accept their 
diagnoses. For men who struggle with being on a monitoring strategy, alternative 
treatments should be offered where clinically appropriate.   
Limitations  
Despite a good survey response rate (61%), the potential for non-response bias must be 
acknowledged. It may be those who were more, or less, anxious chose not to participate. It 
is also possible anxiety levels may be higher in men closer to diagnosis, as suggested 
previously [40]. No measure of risk of progression was included, therefore it was not 
possible to control for this. Equally, disease stage could not be broken down further, so men 
with low and intermediate risk disease were included but we were unable to examine 
differences in outcomes between these groups. We considered men on either AS or WW, 
given the difficulties of determining which regime men were on. No difference in well-being 
was found between the AS or WW groups when analyses were repeated separately, which 
supported combining these groups.  
Conclusions 
Most men on a monitoring pathway for PCa appear to adjust well. An important minority 
adjust less well and need greater support. Results have identified ways in which health 
services can optimise the information and support provided to these men. 
Words: 4496 
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Table 1. Respondent characteristics for men on active surveillance/watchful waiting 
(AS/WW) and men who received active treatment (AT)a 
 
  
AS/WW 
 (n=3,986) AT (n=12,740)   
  N % N % pb 
Age group         
0.20 
<55 97 2.4 310 2.4 
55-64 703 17.6 2,271 17.8 
65-74 1,908 47.9 6,225 48.9 
74-85 1,124 28.2 3,537 27.8 
85+ 154 3.9 397 3.1 
Ethnicity 
    
0.06 
White 3,785 95.0 12,015 94.3 
Non-white 95 2.4 376 3.0 
Unknown 106 2.7 349 2.7 
Socioeconomic deprivation quintile 
    
0.02 
1 (least deprived) 1,139 28.6 3,339 26.2 
2 1,028 25.8 3,467 27.2 
3 834 20.9 2,639 20.7 
4 559 14.0 1,835 14.4 
5 (most deprived) 344 8.6 1,209 9.5 
Unknown 82 2.1 251 2.0 
Marital status         
0.09 
Married/civil partnership 3,154 79.1 10,226 80.3 
Separated/divorced 280 7.0 946 7.4 
Widowed 297 7.5 805 6.3 
Single 157 3.9 456 3.6 
Other 54 1.4 173 1.4 
Unknown 44 1.1 134 1.1 
Sexuality 
    
0.36 
Heterosexual 11976 97.4 3749 97.2 
Homosexual 92 0.7 38 1.0 
Bisexual 42 0.3 17 0.4 
Don't know/prefer not to answer 183 1.5 52 1.3 
Unknown 447 3.6 130 3.4 
Other long term conditions 
    
0.34 
None 1,216 30.5 3,714 29.2 
1 1,408 35.3 4,565 35.8 
2 767 19.2 2,453 19.3 
3 317 8.0 1,119 8.8 
4 or more 278 7.0 889 7.0 
Employment status 
    0.27 Employed 840 21.1 2,789 21.9 
Unemployed 82 2.1 312 2.4 
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Retired 2,945 73.9 9,211 72.3 
Other 15 0.4 62 0.5 
Unknown 104 2.6 366 2.9 
Carer status c         
0.57 
Yes 929 23.3 3,026 23.8 
No 2,897 72.7 9,209 72.3 
Unknown 160 4.0 505 4.0 
Previous consultation with health 
professionals for mental health or 
alcohol/drug problem d         
0.46 
Yes 675 16.9 2,223 17.4 
No 3,201 80.3 10,171 79.8 
Unknown 110 2.8 346 2.7 
a Men who received one of the 8 most common treatments: Surgery; Androgen Deprivation therapy (ADT); 
External Beam radiotherapy (EBRT); Brachytherapy; EBRT + ADT; Surgery + EBRT/ADT; Systemic therapy + ADT; 
Systemic therapy + EBRT (+/- ADT).  
b Chi-square tests excluding the Unknown groups.  
c ĂƌĞƌƐƚĂƚƵƐƌĞĨĞƌƐƚŽƚŚĞƋƵĞƐƚŝŽŶ “ĚŽǇŽƵůŽŽŬĂĨƚĞƌ ?ŽƌŐŝǀĞĂŶǇŚĞůƉŽƌƐƵƉƉŽƌƚ ?ŶŽƚƉĂƌƚŽĨǇŽƵƌƉĂŝĚ
employment) to family members, friends, neighbours or others because of either: long term physical or mental 
health disability, or problems relating ƚŽŽůĚĂŐĞ ? ? 
d Previous consultation with Health Professionals refers tŽƚŚĞƋƵĞƐƚŝŽŶ “ŚĂǀĞǇŽƵĞǀĞƌŝŶǇŽƵƌůŝĨĞƚŝŵĞƐĞĞŶĂ
ŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůĨŽƌƉƌŽďůĞŵƐǁŝƚŚǇŽƵƌĞŵŽƚŝŽŶƐŽƌŶĞƌǀĞƐŽƌǇŽƵƌƵƐĞŽĨĂůĐŽŚŽůŽƌĚƌƵŐƐ ? ? 
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Table 2. Psychological outcomes in men on active surveillance/ watchful waiting (AS/WW) 
and men who received active treatment (AT) 
 
SWEMWBS Poor well-being   Unadjusted model Adjusted modela 
  No (>19.25) zĞƐ ?A? ? ? ? ? ? ?p OR 95% CI OR 95% CI 
AT 10,335 (86.1%) 1,665 (13.9%) 
0.02 
1.00 
 
1.00 
 AS/WW 3,285 (87.7%) 462 (12.3%) 0.87 0.78-0.97 0.86 0.76-0.97 
K6 Severe mental distress 
 
Unadjusted model Adjusted modela 
  No (<19) Yes (19) p OR 95% CI OR 95% CI 
AT 11,534 (94.9%) 656 (5.4%) 
0.05 
1.00 
 
1.00 
 AS/WW 3,625 (95.6%) 174 (4.6%) 0.84 0.71-1.00 0.90 0.74-1.08 
 
a Adjusted for age, ethnicity, socioeconomic deprivation, other long term conditions, marital status, 
employment status, carer status 
OR: odds ratios; CI: confidence interval  
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6. Re-establishing a sense
of security and letting go 
of fears vs. struggling 
with uncertainty
4. Acceptance  and 
normalisation of PCa
vs. struggling to 
accept and normalise
the diagnosis
2. Positive reframing of 
the threats of PCa vs. 
holding a generalised 
view of cancer 
Dismantling the 
threats of cancer 
and the impact of 
being on a 
monitoring pathway
5. Preserving the normal 
self vs. holding greater 
illness centrality 
3. Taking an 
independent approach 
and getting on with life 
vs. struggling to get on 
with life
1. Appraisal of PCa as a 
minimal threat vs. 
significant threat 
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